Form 10-Q · Quarterly report
Zimmer Biomet 10-Q, filed Aug 5, 2026
- Filed
- CIK
- 0001136869
- Accession no.
- 0001193125-26-335044
Summary
Zimmer Biomet reported second-quarter 2026 net sales of $2.18 billion, up 4.8% from a year earlier, with U.S. sales up 5.6% to $1.24 billion and international sales up 3.7% to $937 million. Sales growth was driven partly by the Paragon 28 acquisition, increased ROSA Robot and bone cement sales, and market growth, while global selling prices had a negative 0.8% effect on year-over-year sales.
Key points
- Net sales for the six months ended June 30, 2026 were $4.26 billion, up 7.0% from the prior-year period.
- Technology & Data, Bone Cement and Surgical sales rose 21.1% in the quarter, primarily on strong ROSA Robot and bone cement sales.
- The Paragon 28 acquisition contributed 0.7 percentage points of volume growth in the quarter and 2.3 percentage points over six months.
- Operating profit was 15.0% of net sales in the quarter, compared with 14.4% a year earlier.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Results of Operations We review sales by two geographies, the United States and International, and by the following product categories: Knees; Hips; S.E.T. (Sports Medicine, Upper Extremities, Foot and Ankle; Trauma, Craniomaxillofacial and Thoracic); and Technology & Data, Bone Cement and Surgical. This sales analysis differs from our reportable operating segments, which are based upon our senior management organizational structure and how we allocate resources toward achieving operating profit goals. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.